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Aims: Small conductance Ca2+-activated K+ channels (SK channels, KCa2) are a new
target for treatment of atrial fibrillation (AF). AP30663 is a small molecule inhibitor of KCa2
channels that is currently in clinical development for treatment of AF. The aim of this study
is to present the electrophysiological profile and mechanism of action of AP30663 and its
efficacy in prolonging atrial refractoriness in rodents, and by bioinformatic analysis
investigate if genetic variants in KCNN2 or KCNN3 influence the expression level of
these in human heart tissue.
Methods and Results: Whole-cell and inside-out patch-clamp recordings of
heterologously expressed KCa2 channels revealed that AP30663 inhibits KCa2 channels
with minor effects on other relevant cardiac ion channels. AP30663 modulates the KCa2.3
channel by right-shifting the Ca2+-activation curve. In isolated guinea pig hearts AP30663
significantly prolonged the atrial effective refractory period (AERP) with minor effects on the
QT-interval corrected for heart rate. Similarly, in anaesthetized rats 5 and 10 mg/kg of
AP30663 changed the AERP to 130.7±5.4% and 189.9±18.6 of baseline values. The
expression quantitative trait loci analyses revealed that the genome wide association
studies for AF SNP rs13376333 in KCNN3 is associated with increased mRNA expression
of KCNN3 in human atrial appendage tissue.
Conclusions: AP30663 is a novel negative allosteric modulator of KCa2 channels that
concentration-dependently prolonged rodent atrial refractoriness with minor effects on the
QT-interval. Moreover, AF associated SNPs in KCNN3 influence KCNN3 mRNA
expression in human atrial tissue. These properties support continued development of
AP30663 for treatment of AF in man.
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Atrial fibrillation (AF) is the most common cardiac arrhythmia
affecting more than 30 million people worldwide, a number that
is rising partly because of the aging population and better
detection. AF is associated with 2- and 1.5 fold increases in
risk of all-cause mortality in woman and men respectively, and
an increased risk of heart failure and stroke (Kirchhof et al.,
2016). Management of patients with AF has improved, but
pharmacological rhythm control therapy is still limited by
moderately effective drugs with potentially serious extra-
cardiac or ventricular adverse effects (Waks and Zimetbaum,
2016). Hence, novel pharmacological rhythm control therapies
are warranted.
The small conductance calcium activated potassium channel
(SK, KCa2), encoded by the KCNNX gene is a new drug target for
treatment of AF (Heijman and Dobrev, 2017). As the name
implies, KCa2 channels are potassium channels activated by
intracellular calcium. Three subtypes of KCa2 channel alfa-
subunits exists (KCa2.1–3, SK1–3) and in the human atria
KCa2.2 and KCa2.3 predominate (Skibsbye et al., 2014).
Genome wide association studies (GWAS) for AF have
identified single nucleotide polymorphisms (SNPs) in KCNN2
and KCNN3 that are highly associated with AF (Ellinor et al.,
2010; Ellinor et al., 2012; Christophersen et al., 2017). Preclinical
studies showed that KCa2 channels during sinus rhythm as well
as during AF play a more prominent role in atria as compared to
ventricles in several species including man (Tuteja et al., 2005; Li
et al., 2009; Diness et al., 2010; Qi et al., 2014; Skibsbye et al.,
2014; Haugaard et al., 2015; Diness et al., 2017), thereby
exhibiting a functional atrial specificity. In atrially tachy-paced
pigs that were resistant to pharmacological cardioversion of AF
with vernakalant, negative allosteric modulation of the KCa2
channel converted AF to sinus rhythm (Diness et al., 2017). In
the current study, we first investigate if genetic variants (SNPs) in
KCNN2 or KCNN3 found in GWAS to be associated with AF
influence the expression level of KCNN2 or KCNN3 in human
atrial or ventricular tissue. Next, we present the ion channel
profile, mode of action, and in vitro, ex vivo and in vivo effects of
the clinical candidate AP30663.MATERIALS AND METHODS
Expression Quantitative Trait Loci
Analyses
The expression quantitative trait loci analyses (eQTL) effects of
the AF GWAS associated SNP rs337711 on KCNN2 and SNP
rs13376333 on KCNN3 were investigated in the Genotype-Tissue
Expression (GTEx) database, release v05-08-15, using default
dashboard analytics setup. GTEx data gene expression was
measured using RNA-sequencing with Illumina TruSeq library
and genotyping was done using whole genome sequencing on an
illumina HiSeq X machine (Carithers et al., 2015). For eQTL
replication we used the Advanced Study of Aortic Pathology
(ASAP) cohort of left-ventricular heart tissue, measured usingFrontiers in Pharmacology | www.frontiersin.org 2Affymetrix ST 1.0 Arrays and genotyping was done using
Illumina Human 610W-Quad Beadarrays (Folkersen et al.,
2011). The statistical calculation was performed using a linear
additive model, where genotype was encoded as 0, 1, or 2 and
used as explanatory variable, with gene expression level as
response variable.
In Vitro Electrophysiology
The potency of AP30663 was assessed in HEK cells stably
expressing rat NaV1.5 or human CaV1.2, KCa2.1, KCa2.2 or
KCa2.3 channels and CHO cell line stably expressing human
KV11.1 using the automated patch-clamp system, Qpatch 16
(Sophion, Ballerup, Denmark) at room temperature. The effect of
AP30663 on heteromeric KV11.1a and KV11.1b channels was
addressed by manual patch clamping. Inside out patch-clamp
recordings were performed on HEK cells stably expressing
human KCa2.3 channels using a HEKA EPC9 amplifier and the
Patchmaster software (HEKA Elektronik, Germany). Effects of
AP30663 on late NaV1.5 currents were addressed by manual
whole-cell patch-clamping using HEK cells transiently
transfected with human NaV1.5 in the absence and presence of
ATXII. The effect of AP30663 was also assessed on the currents
conducted by Kir2.1 (IK1); KV7.1/KCNE1 (Iks); KV4.3/KCHIP2
(Ito), Kir3.1/Kir3.4 (IKACh); and KV1.5 (IKur) using the two-
electrode voltage-clamp method on Xenopus oocytes, as
previously described (Diness et al.). See details of in vitro
electrophysiology methods in Supplementary Methods
and Materials.
Animal Experiments
Animal experiments were performed under the license from the
Danish Ministry of justice (2018-15-0201-01430 & 2016-15-
0201-00850) and in accordance with the Danish guidelines for
animal experiments according to the European Commission
Directive 86/609/EEC.
Isolated Perfused Guinea Pig Heart Experiments
A total of 12 female and 6 male Guinea pig hearts were used. In
brief after anesthesia the hearts were removed and retrogradely
perfused with Krebs–Henseleit solution via the aorta. Hearts
were mounted in a Langendorff set-up (Hugo Sachs Elektronik,
Germany) and electrocardiograms (ECG) were obtained with
three ECG electrodes placed near the heart. A pacing electrode
on the right atrium was used to stimulate the atria and measure
atrial refractory periods (AERP).
After the baseline recording, three 20-min episodes followed in
which the heart was perfused with increasing concentrations of
AP30663 (1, 3, and 10 µM). Timematched control hearts underwent
the same procedure. For details see Supplementary Methods.
Irwin
An observational Irwin test for assessing CNS exposure of
AP30663 was performed in mice. A total of three NMRI mice
(Taconic Europe, Lille Skensved, Denmark) weighing 40 to 60 g
were used. After injection of a bolus dose of 10 mg/kg AP30663
in the tail vein, the mice were observed for up to 30 min.May 2020 | Volume 11 | Article 610
Bentzen et al. Novel KCa2 ModulatorClosed Chest Rat AERP
A total of seven male Sprague–Dawley rats were used for the
closed chest preparations. The rats were anaesthetized with 3 %
isofluran/oxygen and catheterized to allow for drug infusion and
intra cardiac pacing. The AERP was measured by applying
electrical stimulation. Baseline AERP recordings were made
every fifth minute for 20 min. Hereafter, two 20-min episodes
followed in which the animal was injected with increasing doses
of AP30663 (5 and 10 mg/kg) or equivalent volumes of vehicle.
AERP was measured 0.5, 2, 4, 6, 10, and 15 min after each
injection. For details see Supplementary Methods.
Drugs and Solutions
AP30663 was solubilized in DMSO stock concentrations of 10
mM for in vitro experiments. The highest concentration of
DMSO was 0.1%. For in vivo experiments, 5 mg/ml AP30663
were dissolved in a vehicle consisting of 50% polyethylene glycol
(PEG) 400 (Merck, Germany) and 50% sterile saline (PanReac
AppliChem, Germany).
Data Analysis
In vitro data were extracted from PatchMaster or Sophion
QPatch Assay Software and analyzed using GraphPad Prism 7.
For detailed description, see Supplementary Methods. Data are
summarized as mean ± SEM.
In vivo and ex vivo experiments were analyzed using
GraphPad Prism software. LabChart software was used for
analyzing the following ECG parameters: QT, PR, RR, QRS.
The QT-interval corrected for heart rate, QTcH, was calculated
as described in Holzgrefe et al. (2014) using the guinea pig
specific formula:
QTcH = QT=(RR=0:28)0:7861 :
Continuous data are summarized using the mean ± SEM.
Multiple unpaired t-tests without assuming consistent standard
deviations and using Holm-Sidaks correction for multiple
comparisons were used to compare the AP30663 groups to their
respective TMC. P values < 0.05 were considered significant and
are given with three decimals. Manuscript Formatting.RESULTS
AF-Associated SNPs in KCNN3 Influences
KCNN3 mRNA Expression in Human
Atrial Tissue
We found that the minor allele T of SNP rs13376333 was
associated with higher mRNA expression of KCNN3 in the
GTEx atrial appendage samples (Figure 1) (P = 0.0223, n =
264). In the one other GTEx heart-related tissue available, the left
ventricle, there was also a trend towards increased expression
with the minor allele A, although not statistically significant (P =
0.0818, n = 272). Additionally, we observed the same effect in the
lung tissue (P = 2.13e-8) and in one brain region tissue (the BA24
region, P=0.0162). The cardiac eQTL effect was replicated in
independent samples of left ventricular biopsies from patientsFrontiers in Pharmacology | www.frontiersin.org 3undergoing surgery in the ASAP study, also with the minor allele
T resulting in increased expression (P=0.0162, n= 127). In
comparison SNP rs337711 was not associated with atrial or
ventricular changes in KCCN2 mRNA expression (P = 0.6 and
P = 0.1, respectively).
AP30663 Inhibits KCa2 Channels by
Modifying the Calcium Sensitivity of
the Channel
AP30663 inhibited the KCa2 current in a concentration-
dependent manner (Figures 2A–C). The concentration
response curves show that AP30663 inhibits all KCa2 channel
subtypes but with a slightly lower potency on KCa2.1 (IC50=
2.29 ± 0.22 µM; KCa2.2, IC50 =1.46 ± 0.28 µM; KCa2.3, IC50=
1.09 ± 0.09 µM) (see Figures 2D, E).
To investigate the inhibitory mechanism of AP30663, we
performed inside out patch-clamp experiments on HEK cells
expressing KCa2.3 (Figure 3). In the absence of AP30663 the
KCa2.3 channel had an EC50 for calcium activation of 0.33 ±
0.02 µM and was fully active at 3 µM. However, in the presence of
7 µM AP30663, 10 µM of calcium is needed to achieve full
activation, and the EC50 for calcium activation is shifted to 1.50 ±
0.12 µM (EC50 baseline vs. AP30663: P < 0.0001). In addition to
shifting the calcium activation curve, meaning that higher
concentrations of calcium are needed to activate the channel,
AP30663 also significantly decreased the Hill slope of the
calcium activation curve from 4.4 ± 0.5 to 1.4 ± 0.1 (slope
baseline vs. AP30663: P < 0.0001).
Ion Channel Selectivity Profile of AP30663
AP30663 was tested on a panel of cardiac ion channels to
determine the functional selectivity profile of the compound.
Automated whole-cell patch-clamp recordings of hKV11.1aFIGURE 1 | eQTL effects of rs13376333 on KCNN3. Y-axis indicates
normalized expression value of KCNN3 according to the GTEx standard
analysis pipeline (Carithers et al., 2015). The figure shows that the expression of
KCNN3 in atrial appendage is increased in the 23 GTEx individuals with the
rs13376333-T/T genotype, as compared to both the 102 heterozygote (C/T)
GTEx individuals and the 139 individuals that are major allele homozygote (C/C).
Having the T-allele have also been shown to increase risk of AF (Ellinor et al.,
2010; Ellinor et al., 2012; Christophersen et al., 2017). These findings were
replicated in an independent eQTL data (P = 0.0162, n = 127).May 2020 | Volume 11 | Article 610
Bentzen et al. Novel KCa2 Modulatorchannels revealed that AP30663 inhibited the IKr current with an
IC50 value of 15.1 ± 2.1 µM (Figure 4A). In comparison when
tested by manual patch clamp at 35°C, on HEK cells transfected
with both cardiac isoforms KV11.1a and KV11.1b, AP30663 was
estimated to have an IC50 of 4.0 ± 1.5 µM. 10 µM AP30663 did
not significantly affect Kir3.1/Kir3.4 (IKACh), KV1.5 (IKur), KV7.1/Frontiers in Pharmacology | www.frontiersin.org 4KCNE1 (IKs), KV4.3/KChiP2 (Ito) and Kir2.1 (IK1) channels
Figure 4B). AP30663 did not significantly inhibit the current
mediated by CaV1.2 (ICa) (inhibition by 30 µM: 4±7 %). The
effects on peak NaV1.5 channel current (INa) were investigated by
automated patch-clamp experiments, and AP30663 in 10 µM did
not affect INa (4±1% inhibition) (Figure 4B).A
B
C
D E
FIGURE 2 | AP30663 inhibits hKCa2 channels. The effect of increasing concentrations of AP30663 was investigated by automated whole-cell patch-clamping in
HEK cells stably expressing human KCa2 channels. Currents were elicited by applying a depolarizing voltage ramp protocol from −80 mV to +80 mV for 200 ms from
a holding potential of 0 mV in symmetrical K+ solutions. Current–voltage recordings are depicted in the left panel for KCa2.1 (A), KCa2.2 (B) and KCa2.3 (C) before
(black) and after application of 1 µM (red), 10 µM (green) and 30 µM (blue) AP30663. Current-time plots (right panel) showing the effect of increasing concentrations
of AP30663 on the for KCa2.1 (A), KCa2.2 (B), and KCa2.3 (C) currents measured at a membrane potential of −80 mV. (D) Concentration–response curve of
AP30663 on KCa2.1 (light gray), KCa2.2 (dark gray), and KCa2.3 (black). (E) Comparison of IC50 values for the 3 KCa2 channel subtypes. (KCa2.1, n = 9; KCa2.2, n =
19; and KCa2.3, n = 16). **p < 0.01.May 2020 | Volume 11 | Article 610
Bentzen et al. Novel KCa2 ModulatorTo determine if AP30663 had any effect on the late INa, we
conducted a set of manual patch-clamp experiments on HEK
cells transfected with the human NaV1.5 channel. Because of its
small size, it is customary to co-apply the sea anemone toxin
ATXII to augment late INa, and to use the sodium channel toxin
tetrodotoxin (TTX) at the end of the experiment to inhibit
residual late INa (Isenberg and Ravens, 1984; Maltsev et al.,
1998). In Figure 4C, it can be seen how ATXII slows the
inactivation of NaV1.5 and causes a small but relevant increaseFrontiers in Pharmacology | www.frontiersin.org 5of the late current. From the time plot in Figure 4D, it can be
appreciated that ATXII in our hands causes a continuous
increase in the late INa amplitude. Hence, a steady state current
is never achieved, and therefore judging the effect of AP30663
solely based on changes in late INa amplitude would be difficult.
To circumvent this, we quantified the effect of 10 µM AP30663
on ATXII augmented late INa by comparing the changes in the
slope of the late INa vs time plot. From the bar graph that
summarizes the effect of AP30663 on the slope from 14A
B
C
D
FIGURE 3 | AP30663 shifts the calcium activation curve of hKCa2.3 channels. Current-voltage recordings (A) and corresponding current-time plots of KCa2.3
measured using the inside-out patch-clamp exposed to different free calcium concentrations, in the absence (B) (black) or presence of AP30663 7 µM (C) (red). (D)
Calcium activation curves for KCa2.3 in the absence (black, n = 6) or presence of AP30663 7 µM (red, n = 6). Currents were measured at a membrane potential of
−80 mV.May 2020 | Volume 11 | Article 610
Bentzen et al. Novel KCa2 Modulatorexperiments it can be concluded that 10 µM AP30663 inhibits
the late INa (Figure 4E).
AP30663 Prolongs the Atrial Refractory
Period With Small Effects on Ventricular
Repolarization—Functional Atrial Selectivity
A well-known anti-arrhythmic mechanism of rhythm control
therapeutics is to prolong atrial refractoriness. After a baseline
period the effects of increasing concentrations of AP30663 (1,
3, and 10 µM) on AERP in isolated female guinea pig heartsFrontiers in Pharmacology | www.frontiersin.org 6were investigated. From Figure 5, it can be appreciated that
AP30663 increases AERP in a concentration-dependent
manner, while QTcH is prolonged to a much lesser degree.
To take into account baseline differences we evaluated the
effect of AP30663 by comparing Ddrug-baseline between TMC
and AP30663 groups for each concentration (Table 1). From
this it can be observed that AP30663 significantly prolongs
AERP at all concentrations, slows the heart rate in 3 and 10
µM, prolongs the QRS in 10 µM and prolongs the PQ-interval
and QTcH-interval. The latter albeit to a much lesser extentA B
C
D E
FIGURE 4 | Ion channel selectivity profile of AP30663. (A) Concentration-response curve of the effect of increasing concentrations of AP30663 on KV11.1a
recorded by automated whole-cell patch-clamp (n = 4). (B) % inhibition by 10 µM AP30663 on Kir3.1/Kir3.4 (IKACh, n = 6), KV1.5 (IKur, n = 5), KV7.1/KCNE1 (IKs, n =
5), KV4.3/KChiP2 (Ito, n = 5), and Kir2.1 (IK1, n = 5) using two-electrode voltage-clamp and NaV1.5 (INa, n = 11), CaV1.2 (ICa, n = 3; 30 µM) using automated whole-
cell patch-clamping. (C) Current traces of the whole-cell Na+ current before and after application of ATXII recorded from HEK293 cells transiently transfected with
hNaV1.5 (dotted box demonstrates where the late-sodium current was analyzed). (D) Late-sodium current amplitudes as a function of time. (E) Effect of compounds
on the slope of the late-sodium current vs time plot. The slope was found by linear regression on the last 10 points of each liquid period (n = 14).May 2020 | Volume 11 | Article 610
Bentzen et al. Novel KCa2 Modulator(~8 ms) as compared to the effects of AP30663 on atrial
refractoriness (10–50 ms). Similar experiments were
conducted in male guinea pigs. No sex differences were
observed (see Supplementary Figure 1 and Supplementary
Table 1).AP30663 Prolongs Atrial Refractoriness
In Vivo
To investigate the in vivo effects of AP30663, male rats were
infused with increasing doses of AP30663 (5 and 10 mg/kg)
or corresponding volumes of vehicle (1 and 2 ml/kg), while
intracardiac recordings of AERP were performed. The AERP
was significantly prolonged by 5 mg/kg and 10 mg/kg of
AP30663 to 143% and 250% of TMC values (Figure 6).Frontiers in Pharmacology | www.frontiersin.org 7AP30663 Does Not Impair Coordination in
Mice
KCa2 channels are expressed in the brain including cerebellum,
and inhibition of these may lead to motor function impairment
(Simó-Vicens et al., 2017). An observational Irwin test for
assessing CNS exposure of AP30663 was performed in mice.
Neither CNS related adverse effects nor other adverse effects were
observed within 30 min of injection of 10 mg/kg i.v. AP30663
(n = 3, data not shown).DISCUSSION
KCa2 channels are widely expressed in the body. In the heart,
KCa2 channels are functionally more important forA B
C D
E F
FIGURE 5 | AP30663 prolongs the atrial refractory period in isolated perfused female guinea pig hearts. (A) Monophasic action potential recording recorded from
the atrium of an isolated perfused guinea pig heart, during investigation of the atrial effective refractory period (AERP). Ten pacing stimuli (S1) are delivered at fixed
basic cycle length of 200 ms, and for every 10th beat, an extra stimulus (S2 marked by * in the recording) is applied with 1 ms increments (for clarity not all S2 are
shown). Notice how the first S2 does not result in an atrial action potential, whereas the second S2 (+1 ms) elicits an action potential. Graph demonstrating the effect
of increasing concentrations of AP30663 on AERP (B), QTcH-interval (C), heart rate (D), PQ-interval (E), and QRS-duration (F) as compared with time matched
control experiments (TMC) (AP30663, n = 6; TMC, n = 6).May 2020 | Volume 11 | Article 610
Bentzen et al. Novel KCa2 Modulatorrepolarization of the atria as compared to the ventricles (Diness
et al., 2010; Qi et al., 2014; Skibsbye et al., 2014; Zhang et al.,
2014; Haugaard et al., 2015; Diness et al., 2017). Pharmacological
experiments on mice, rats, guinea pigs, rabbits, pigs, goats, dogs
and horses have demonstrated that KCa2 channel inhibitors can
prolong atrial refractoriness, terminate AF and prevent
reinduction of AF (Diness et al., 2010; Diness et al., 2011; Qi
et al., 2014; Haugaard et al., 2015; Gatta et al., 2019). In addition,
we previously demonstrated that KCa2 channel inhibition can
cardiovert vernakalant-resistant AF in atrially tachypaced pigs
(Diness et al.), and prolong atrial but not ventricular APD in
human multicellular preparations (Skibsbye et al., 2014).
Moreover, genome wide association studies have put the KCa2
channel (KCNN2 and KCNN3) on the list of genes that are highly
associated with AF (Ellinor et al., 2010; Ellinor et al., 2012;
Christophersen et al., 2017). KCa2 channels thus constitute an
interesting novel drug target for treatment of AF.Frontiers in Pharmacology | www.frontiersin.org 8The advances of genomics and transcriptomics allow us to study
possible associations between genetic variants and their influence on
mRNA expression levels (eQTL analyses), and hence guide drug
discovery.Herewe performed eQTLanalyses and found that theAF-
increasing variant of rs13376333 is associated with increasedmRNA
expression of KCNN3 in human atrial tissue. This suggests that
increased KCa2 channel mRNA is associated with AF, and hence
points towards the possibility of developing KCa2 channel inhibitors
for the treatment of AF. To this end, we have developed AP30663.
AP30663 is an inhibitor of KCa2 channels with no KCa2-subtype
selectivity amongst KCa2.2 and KCa2.3 but a slightly lower potency
on KCa2.1, which is the KCa2 subtype found to be least expressed in
the human heart (Skibsbye et al., 2014). AP30663 inhibits the KCa2
channels when applied to both the intra- and extracellular side of the
plasma membrane. From inside-out recordings we found that
AP30663 significantly shifts the EC50 for calcium activation and
lowers theHill-slope, suggesting that AP30663 decreases the calcium
sensitivity of KCa2 channels thereby acting as a negative allosteric
modulator of the channel. This is similar to what has been reported
for two other KCa2 inhibitors, NS8593 and AP14145 (Strøbaek et al.,
2006; Simó-Vicens et al., 2017, 14145). Likewise, a changed Hill-
slopewas also observed forNS8593 andAP14145 andmay indicate a
loss of calcium cooperativity. AP30663 was functionally tested on a
broad panel of other cardiac ion channels, and 10 µM AP30663 did
not significantly affect the Kir3.1/Kir3.4 (IKACh), KV1.5 (IKur), KV7.1/
KCNE1 (IKs), KV4.3/KChiP2 (Ito), Kir2.1 (IK1) and CaV2.1 (ICa,L)
channels (the latter tested up to 30 µM). A concentration-dependent
inhibition of KV11.1 by AP30663 was observed, with a calculated
IC50 of 15 or 4 µM depending on assay type. The difference in
potency can likely be explained by the differences in temperature,
voltage protocols, and KV11.1 isoforms investigated (homomeric
KV11.1a vs. heteromeric KV11.1a/KV11.b channels). Minor effects of
10 µM AP30663 on peak INa, but a significant inhibition of the late
INa was observed. Selective inhibition of late INa is known to suppress
ventricular arrhythmias, especially in settings of prolonged
ventricular repolarization (Antzelevitch et al., 2004; Wu et al.,
2004; Undrovinas and Maltsev, 2008; Antoons et al., 2010;
Antzelevitch et al., 2011). Late INa has been found in atrial
cardiomoycytes from patients with and without AF, although only
at room temperature and not at physiological temperatures (Poulet
et al., 2015). Ranolazine, which inhibits various ion channels in
addition to also inhibiting the late INa, has demonstrated anti-AF
efficacy in a number of studies (Scirica et al., 2007;Miles et al., 2011).
Experimental evidence, however, indicates that ranolazine works
against AF only at concentrations that also inhibit IKr and peak INa in
atria (Burashnikov and Antzelevitch, 2013; Du et al., 2014). Late INa
is reduced at higher heart rates and would not be expected to play a
significant role during tachyarrhythmias such as AF (Burashnikov
and Antzelevitch, 2013). Whether or not the inhibition of late INa
seen by 10µMAP30663 contributes to any antiarrhythmic activity of
the compound is therefore unknown.
AP30663 consistently led to concentration- and dose-dependent
prolongation of atrial refractoriness in ex vivo and in vivo
experiments. Even though KCa2 channels are expressed in both
atria and ventricles in guinea pigs (Kirchhoff et al., 2019), targeting
KCa2 channel has previously been shown to be atrial selective in aTABLE 1 | Effect of AP30663 on isolated perfused female guinea pig hearts.
AP30663 concentration 1µM 3µM 10µM
AERP (ms) TMC −4 ± 1 −7 ± 1 −2 ± 2
AP30663 10 ± 3 20 ± 3 47 ± 4
P 0.002 <0.001 <0.001
QTcH (ms) TMC 0 ± 1 −2 ± 2 −3 ± 3
AP30663 8 ± 2 8 ± 3 7 ± 5
P 0.029 0.053 0.099
HR (BPM) TMC −6 ± 3 −7 ± 4 −12 ± 5
AP30663 −8 ± 4 −24 ± 4 −56 ± 2
P 0.672 0.019 <0.001
QRS (ms) TMC 0 ± 1 1 ± 1 1 ± 1
AP30663 0 ± 0 3 ± 1 6 ± 1
P 0.392 0.203 0.007
PQ (ms) TMC −1 ± 1 1 ± 1 1 ± 3
AP30663 4 ± 2 7 ± 2 12 ± 2
P 0.035 0.024 0.024Changes in AERP, QTcH, HR, PQ, and QRS (Ddrug, baseline) for each group (TMC and
AP30663) calculated at the end of drug period (20, 40, and 60 min). P values refer to the
comparison of D values between TMC and AP30663 groups.A B
FIGURE 6 | AP30663 prolongs the atrial refractory period in vivo in rats and
does not induce CNS related adverse effects in mice. (A) The effect of i.v.
injection of AP30663 or vehicle (time matched control, TMC) on AERP
evaluated in anaesthetized rats using an intracardiac pacing catheter
positioned in the right atria (TMC, n = 4; AP30663, n = 3). (B) Bar graph
depicting the number of mice with CNS related adverse effects triggered by
the i.v administration of AP30663 (10 mg/kg), n = 3. *0,0187, ****< 0,0001.May 2020 | Volume 11 | Article 610
Bentzen et al. Novel KCa2 Modulatorwide range of species, including measurement on human heart
tissue (Diness et al., 2010; Qi et al., 2014; Skibsbye et al., 2014; Zhang
et al., 2014; Haugaard et al., 2015; Diness et al., 2017). Similarly, in
the current study AP30663 was found to predominantly prolong the
atrial refractoriness as compared to ventricular repolarization
(QTcH). The QTcH prolongation (8 ms as compared to TMC)
appeared to reach a plateau already at 1 µM. Considering the in vitro
IC50 of AP30663 on KCa2 (~1 µM) and Kv11.1 (4–15 µM) and the
mRNA expression of KCa2 and KV11.1 channels in guinea pig
ventricles (Kirchhoff et al., 2019), the QTcH prolongation could be
speculated to arise from combined contribution of ventricular KCa2
and Kv11.1 inhibition. The apparent observed plateau seen for QT
prolongation could however also indicate that Kv11.1 inhibition has
a minor impact. At this stage the exact contribution to the minor
QT prolongation from KCa2 and Kv11.1 inhibition can only be
speculative. We did not see any effects of AP30663 on QRS-
duration, which correlates well with the lack of effects on peak
NaV1.5 currents stimulated at 1 Hz. In addition to prolongation of
AERP, the isolated guinea pig heart AP30663 also slows heart rate
and prolongs the PQ-interval, suggesting effects on nodal tissue.
This is in line with findings from mouse demonstrating that
ablation of KCa2.2 reduces the firing of the AV node(Zhang et al.,
2008) and pharmacological inhibition of KCa2 channels by apamin
reduces the spontaneous firing of the sinus node(Torrente et al.,
2017). Sex specific differences in the importance of SK channels for
cardiac ventricular electrophysiology have been reported (Chen
et al., 2018). However, we did not observe any differences in the
response to AP30663 in male and female guinea pigs.
In the brain KCa2 channels contribute to neuronal action
potential after hyperpolarization, and inhibition of the channel is
known to disturb motor output from the cerebellum. Consequently,
AP30663 was designed to have limited CNS exposure, and infusion
of AP30663 to conscious mice confirmed this.CONCLUSION
AP30663 was found to inhibit the KCa2 channel by decreasing
the calcium sensitivity of the channel, while being selective over
several relevant cardiac ion channels. Ex vivo and in vivo
experiments confirmed the ability of the drug to prolong the
AERP in a concentration-dependent fashion with minor effects
on the QT interval. Based on this profile, AP30663 is an
attractive compound for investigating if KCa2 channel
inhibition can be used as a novel antiarrhythmic therapy.LIMITATIONS
Although the calcium shift in calcium sensitivity was only
investigated for KCa2.3 it is likely that the inhibitory
mechanism of AP30663 on KCa2.1 and KCa2.2 is similar based
on the high sequence homology between the three isoforms. The
selectivity of the compound was investigated using
overexpression systems and not on native cardiomyocytes.
Hence, some of the complexity of native cardiac ion channelFrontiers in Pharmacology | www.frontiersin.org 9complexes, which potentially could impact the selectivity of the
compounds, might have been missed. However, the obtained
selectivity data on AP30663 combined with our ex vivo and in
vivo ECG data supports that AP30663 does not have major
impact on other cardiac ion channels. Moreover, for calcium
recordings we only performed 3 experiments, which could limit
the conclusion. However from our ex vivo and in vivo recordings
we did not observe signs of calcium channel inhibition (e.g. PR
interval prolongations and blood pressure drop).DATA AVAILABILITY STATEMENT
All datasets generated for this study are included in the article/
Supplementary Material.ETHICS STATEMENT
The animal experiments were performed under the license from
the Danish Ministry of Justice (2018-15-0201-01430 & 2016-15-
0201-00850) and in accordance with the Danish guidelines for
animal experiments according to the European Commission
Directive 86/609/EEC.AUTHOR CONTRIBUTIONS
SB, RS-V, LF, LA TS, and KM contributed with acquisition,
interpretation and analysis of data. US, MG, and NE contributed
with conception and design of the study. BB and JD wrote the
first draft of the manuscript and interpreted and analysed the
data, and contributed with conception and design of the study.
All authors contributed to manuscript revision, read and
approved the submitted version.FUNDING
This work was supported by the Innovation Fund Denmark,
Wellcome Trust (grant 100406/Z/12/Z), and the European
Union’s Horizon 2020 research and innovation programme
under the Marie Skłodowska-Curie grant agreement 675351.ACKNOWLEDGMENTS
We thank Amer Mujezinovic for expert technical assistance.SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online
at: https://www.frontiersin.org/articles/10.3389/fphar.2020.
00610/full#supplementary-materialMay 2020 | Volume 11 | Article 610
Bentzen et al. Novel KCa2 ModulatorREFERENCES
Antoons, G., Oros, A., Beekman, J. D. M., Engelen, M. A., Houtman, M. J.
C., Belardinelli, L., et al. (2010). Late na(+) current inhibition by
ranolazine reduces torsades de pointes in the chronic atrioventricular
block dog model. J. Am. Coll. Cardiol. 55, 801–809. doi: 10.1016/
j.jacc.2009.10.033
Antzelevitch, C., Belardinelli, L., Wu, L., Fraser, H., Zygmunt, A. C., Burashnikov,
A., et al. (2004). Electrophysiologic properties and antiarrhythmic actions of a
novel antianginal agent. J. Cardiovasc. Pharmacol. Ther. 9 (Suppl 1), S65–S83.
doi: 10.1177/107424840400900106
Antzelevitch, C., Burashnikov, A., Sicouri, S., and Belardinelli, L. (2011).
Electrophysiologic basis for the antiarrhythmic actions of ranolazine. Heart
Rhythm. 8, 1281–1290. doi: 10.1016/j.hrthm.2011.03.045
Burashnikov, A., and Antzelevitch, C. (2013). Role of late sodium channel current
block in the management of atrial fibrillation. Cardiovasc. Drugs Ther. 27, 79–
89. doi: 10.1007/s10557-012-6421-1
Carithers, L. J., Ardlie, K., Barcus, M., Branton, P. A., Britton, A., Buia, S. A.,
et al. (2015). A Novel Approach to High-Quality Postmortem Tissue
Procurement: The GTEx Project. Biopreserv. Biobank. 13, 311–319.
doi: 10.1089/bio.2015.0032
Chen, M., Yin, D., Guo, S., Xu, D.-Z., Wang, Z., Chen, Z., et al. (2018). Sex-specific
activation of SK current by isoproterenol facilitates action potential
triangulation and arrhythmogenesis in rabbit ventricles. J. Physiol. 596,
4299–4322. doi: 10.1113/JP275681
Christophersen, I. E., Rienstra, M., Roselli, C., Yin, X., Geelhoed, B., Barnard,
J., et al. (2017). Large-scale analyses of common and rare variants identify
12 new loci associated with atrial fibrillation. Nat. Genet. 49, 946–952.
doi: 10.1038/ng.3843
Diness, J. G., Sørensen, U. S., Nissen, J. D., Al-Shahib, B., Jespersen, T., Grunnet,
M., et al. (2010). Inhibition of small-conductance Ca2+-activated K+ channels
terminates and protects against atrial fibrillation. Circ. Arrhythm.
Electrophysiol. 3, 380–390. doi: 10.1161/CIRCEP.110.957407
Diness, J. G., Skibsbye, L., Jespersen, T., Bartels, E. D., Sørensen, U. S., Hansen, R. S.,
et al. (2011). Effects on atrial fibrillation in aged hypertensive rats by Ca(2
+)-activated K(+) channel inhibition. Hypertension 57, 1129–1135. doi: 10.1161/
HYPERTENSIONAHA.111.170613
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